Graft-versus-Host Disease: Eyes

Celebrating a Second Chance at Life Survivorship Symposium

April 27 – May 3, 2024



Todd Margolis MD, PhD
Professor and Chair. Department
of Ophthalmology and Visual
Sciences, Washington University
School of Medicine



Ocular GVHD (not just another dry eye)

A practical guide to understanding and management

Todd P. Margolis, M.D., Ph.D.

Alan A. and Edith Wolff Distinguished Professor and Chair Hardesty Department of Ophthalmology and Visual Sciences Washington University St. Louis




2024 SURVIVORSHIP SYMPOSIUM





What is ocular GVHD (oGVHD)?

Immune mediated disease of ocular structures following BMT.





Things that I will talk about

- 1. Primary ocular GVHD (oGVHD)
- 2. Secondary ocular issues (even if primary oGVHD is under control)
- 3. How to manage primary and secondary issues, and who should do it
- 4. Patient expectations





Things I will not talk about (and why)

- 1. Epidemiology of oGVHD
- 2. The pathogenesis of oGVHD
- 3. oGVHD involving the inside of the eye
- 4. Staging/grading of oGVHD
- 5. Lid/lash issues in oGVHD
- 6. Meibomian gland dysfunction in oGVHD




Ocular Anatomy/Terminology






Meibomian glands




Conjunctiva of the upper lid



Layers of the Cornea








What is primary oGVHD?

Lacrimal gland inflammation

Conjunctival inflammation




Conjunctiva = Clear mucous membrane covering the inside of the lids and outside of the eye ball



Why It's Important to Recognize Primary oGVHD?


- i. It requires systemic immune modulatory therapy
- ii. BMT doctors want to know if GVHD is active

Primary oGVHD





Secondary issues








Why It's Important to Recognize Primary oGVHD?


- i. It requires systemic IMT
- ii. BMT doctors want to know if GVHD is active

Primary oGVHD





Secondary issues







Schirmer Testing

Gold standard is performed without topical anesthesia







Ocular Surface Staining

Used to detect ocular surface damage caused by tear deficiency













Corneal Filaments






mucous + strands of corneal epithelial cells



More Severe Complications of Tear Loss



keratinization corneal thinning corneal ulceration

keratinization = production of keratin (waxy skin protein) changing the mucosal epithelial surface from moist and soft, to hard and waxy (skin-like).



oGVHD: Management

Goals:

Improve quality of life (comfort, vision)

Prevent more secondary disease

Pay attention to costs

Minimize doctor visits



oGVHD: Management There is No Magic Bullet

- 1. Systemic therapy: If primary oGVHD is active
- Manage tear deficiency
 - Tear substitutes
 - Block tear drainage
 - Block tear evaporation
 - Scleral contact lens
- 3. Mange complications of tear deficiency
 - Acetyl-cysteine for mucous/corneal filaments
 - Antibiotics to prevent infection
 - All-trans retinoic acid (ATRA) for keratinization
- 4. Control Inflammation



Tear Substitutes

For comfort and protection. Use before eyes start hurting!



Q: Which ones? A: Which ever feel best

Q: Non-preserved? A: Only if reacting to preserved



Eye Drop and Lid Cleaner Toxicity


Lids/conjunctiva



Corneal stroma







Tobradex

Retaine MGD

Clear eyes

Any drop can do this. Even non-preserved and lid cleansers.



Other Lubricant Concerns

Proper instillation




Contaminated products







Block Tear Drainage

punctal plugs






surgical occlusion





Reduce Evaporation


















Corneal Healing with Simple Patching after Failing 'Everything'






Scleral Lens







- Reduce discomfort
- Improve vision
- Protect cornea from further damage
- Resolve corneal damage



Reduce Inflammation with Steroid Eye Drops

- Prednisolone, fluorometholone, loteprednol, dexamethasone
- 2. Major risk: rise in eye pressure >>> cataract
- 3. Rare risk: infection
- 4. 75% will not get pressure rise
- 5. Pressure rise usually occurs within 2 months




Costly Therapies of Questionable Value

- 1. Serum eye drops
- 2. Amniotic membrane
- 3. Topical cyclosporine (Restasis, Cequa, etc)
- 4. Lifitegrast (Xiidra)
- 5. Meibomian gland therapies
- 6. Heparin drops, IVIG drops, DNAse drops
- 7. Varenicline (Tyrvaya)
- 8. Omega-3 fatty acids




Other Common Ocular Issues







Bacterial conjunctivitis



Mucous



SLK (superior limbic keratoconjunctivitis)



Self injury (finger and tissue)



Pearls 1

- Local therapy effective only if systemic GVHD is controlled
- Local therapy is targeted at symptoms
- Do not fear topical steroids
- Beware of self injury (drops, preservatives, tissue, fingers)



Pearls 2

- Leave the damn lids alone!
- Avoid 'get the red out' drops
- Avoid lid/conjunctival surgery
- An experienced eye care provider matters
 - Optometrist (OD) vs Ophthalmologist (MD)
 - Cornea specialist (MD) with oGVHD experience



Thank You!!







Cataract = opacification of the lens

Normal Lens

Cataract










Questions?



Todd Margolis MD, PhD
Professor and Chair. Department of
Ophthalmology and Visual Sciences,

Washington University School of Medicine



Let Us Know How We Can Help You



website: bmtinfonet.org

Email us: help@bmtinfonet.org

Phone: 888-597-7674 or 847-433-3313

Find us on:

Facebook, facebook.com/bmtinfonet

X, twitter.com/BMTInfoNet

